Abstract:TP53 is the most frequently mutated gene in human cancer. It encodes the tumor suppressor protein p53, which suppresses tumorigenesis by acting as a critical transcription factor that can induce the expression of many genes controlling a plethora of fundamental cellular processes, including cell cycle progression, survival, apoptosis, and DNA repair. Missense mutations are the most frequent type of mutations in the TP53 gene. While these can have variable effects, they typically impair p53 function in a dominant-negative manner, thereby altering intra-cellular signaling pathways and promoting cancer development. Additionally, it is becoming increasingly apparent that p53 mutations also have non-cell autonomous effects that influence the tumor microenvironment (TME). The TME is a complex and heterogeneous milieu composed of both malignant and non-malignant cells, including cancer-associated fibroblasts (CAFs), adipocytes, pericytes, different immune cell types, such as tumor-associated macrophages (TAMs) and T and B lymphocytes, as well as lymphatic and blood vessels and extracellular matrix (ECM). Recently, a large body of evidence has demonstrated that various types of p53 mutations directly affect TME. They fine-tune the inflammatory TME and cell fate reprogramming, which affect cancer progression. Notably, re-educating the p53 signaling pathway in the TME may be an effective therapeutic strategy in combating cancer. Therefore, it is timely to here review the recent advances in our understanding of how TP53 mutations impact the fate of cancer cells by reshaping the TME.

p53 and its mutants in tumor cell migration and invasion

p53 signaling in cancer progression and therapy

Mutant p53 as a guardian of the cancer cell

Mutant P53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Functional Diversity of P53 in Human and Wild Animals

Crosslink between p53 and metastasis: focus on epithelial–mesenchymal transition, cancer stem cell, angiogenesis, autophagy, and anoikis

Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

p53, cancer and the immune response

Mutant P53 Drives Pancreatic Cancer Metastasis Through Cell-Autonomous PDGF Receptor Β Signaling

Gain-of-function mutant p53 in cancer progression and therapy

[Advances on Mutant P53 Research].

P53 Mutation and Deletion Contribute to Tumor Immune Evasion

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

Gain of Function of P53 Cancer Mutants in Disrupting Critical DNA Damage Response Pathways

Opposing roles of wild-type and mutant p53 in the process of Epithelial to Mesenchymal Transition

Mutant p53 in cancer therapy-the barrier or the path.

Mutant p53 regulates cancer cell invasion in complex three-dimensional environments through mevalonate pathway-dependent Rho/ROCK signaling.

p53: 800 million years of evolution and 40 years of discovery

The limitless role of p53 in cell cycle machinery: Good news or bad news?

Actin-Dependent Mechanism of Tumor Progression Induced by a Dysfunction of p53 Tumor Suppressor